These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23570092)

  • 1. Update: NCCN non-small cell lung cancer clinical practice guidelines.
    Ettinger DS; Kris MG
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-9-13. PubMed ID: 23570092
    [No Abstract]   [Full Text] [Related]  

  • 2. Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines.
    Ettinger D; Johnson B
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S17-21. PubMed ID: 16280105
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
    Gandara DR; Wakelee H; Calhoun R; Jablons D
    J Thorac Oncol; 2007 Jul; 2(7 Suppl 3):S125-7. PubMed ID: 17603308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
    Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U
    Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811
    [No Abstract]   [Full Text] [Related]  

  • 5. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
    Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
    J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Linden HM; Krohn KA; Livingston RB; Mankoff DA
    Clin Cancer Res; 2006 Oct; 12(19):5608-10. PubMed ID: 17020961
    [No Abstract]   [Full Text] [Related]  

  • 7. FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Gold KA; Erasmus JJ
    J Thorac Oncol; 2015 Aug; 10(8):1131-2. PubMed ID: 26200266
    [No Abstract]   [Full Text] [Related]  

  • 8. [A must: evaluation of adjuvant chemotherapy in bronchogenic cancers by a randomized trial].
    Depierre A; Chastang C; Lebeau B; Clavier J; Milleron B; Brambilla C; Quoix E; Lemarié E
    Rev Pneumol Clin; 1992; 48(2):45-7. PubMed ID: 1329178
    [No Abstract]   [Full Text] [Related]  

  • 9. Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?
    Azzoli CG
    Nat Clin Pract Oncol; 2005 Nov; 2(11):552-3. PubMed ID: 16270095
    [No Abstract]   [Full Text] [Related]  

  • 10. [Personalised treatment of lung cancer].
    Ullrich RT; Zander T; Wolf J; Hallek M
    Dtsch Med Wochenschr; 2012 Oct; 137(42):2179-80. PubMed ID: 23055362
    [No Abstract]   [Full Text] [Related]  

  • 11. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
    Wang Q; Wang H; Li P; Zhu H; He C; Wei B; Ma J; Ma Z
    Am J Med Sci; 2010 Oct; 340(4):321-5. PubMed ID: 20601859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [News for lung cancer care].
    Berghmans T
    Rev Med Brux; 2009 Sep; 30(4):287-91. PubMed ID: 19899375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant chemotherapy for non-small cell lung carcinoma Stage IA p-T1N0M0. A changed "scenario" after the 2009 7th edition of TNM staging system].
    Salvati F; Combi G
    Recenti Prog Med; 2013 Apr; 104(4):159-62. PubMed ID: 23748639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative data from lung cancer trial may change practice guidelines, study designs.
    McNeil C
    J Natl Cancer Inst; 2006 Nov; 98(21):1518-20. PubMed ID: 17077353
    [No Abstract]   [Full Text] [Related]  

  • 15. [The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery].
    De Marinis F; De Petris L
    Suppl Tumori; 2004; 3(4):S50-1. PubMed ID: 15206212
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
    Cerfolio RJ; Ojha B; Mukherjee S; Pask AH; Bass CS; Katholi CR
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):938-44. PubMed ID: 12698159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of adjuvant chemotherapy in NSCLC (stages I to III).
    Coleman MH; Bueno R
    Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Can positron-emission tomography modify the management of non-small-cell lung cancer?].
    Ninane V
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S5-7. PubMed ID: 16719146
    [No Abstract]   [Full Text] [Related]  

  • 19. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.
    Barni S; Maiello E; Di Maio M; Ardizzoni A; Cappuzzo F; Maranzano E; Novello S; Bennati C; Ori A; Rizzoli S; Crinò L;
    Lung Cancer; 2015 Nov; 90(2):234-42. PubMed ID: 26314614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
    Ettinger DS; Wood DE; Aggarwal C; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower M; Gettinger S; Govindan R; Gubens MA; Hennon M; Horn L; Lackner RP; Lanuti M; Leal TA; Lin J; Loo BW; Martins RG; Otterson GA; Patel SP; Reckamp KL; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer KW; Yang SC; Gregory K; ; Hughes M
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1464-1472. PubMed ID: 31805526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.